Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.

García de Lucas MD, Caballero I, Fernández-García JC, Domínguez-Rodríguez M, Moreno-Moreno P, Jiménez-Millán A, Botana-López M, Avilés B, Merino-Torres JF, Soto A, Tejera C, Morales C

Frontiers in endocrinology24 Oct 2023Cited by 6 (Europe PMC)

PMID37955013PMCIDPMC10634592DOI10.3389/fendo.2023.1240279PepBankPUB-37955013

Download PDF PubMedAsk about this study

Jump to 9 results

Summary

ObjectivesSemaglutide is a glucagon-like peptide 1 receptor agonist that improves glycemic control and achieves weight loss in type 2 diabetes (T2D) patients. Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with chronic kidney disease (CKD). Whether or not CKD and its severity influence treatment response remains undetermined.MethodThis is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD. The influence of CKD severity was also addressed. Patients were followed up for 12 months. Primary end-points were glycosylated hemoglobin (HbA1c), weight, and renal outcomes. Secondary end-points included insulin resistance, atherogenic and hepatic steatosis indexes, and changes in antihyperglycemic medications.ResultsA total of 296 and 190 T2D patients without or with CKD, respectively, were recruited. Baseline CKD risk was moderate, high, or very high in 82, 53, and 45 patients, respectively. Treatment reduced HbA1c by 0.90%-1.20%. Relevant differences were seen neither between non-CKD and CKD patients nor among CKD subgroups. Notable weight losses were achieved in both non-CKD and CKD patients. The median reduction was higher in the former at 6 months (5.90 kg vs. 4.50 kg, P = 0.008) and at end of study (6.90 kg vs. 5.00 kg, P = 0.087). A trend toward slightly lower weight losses as CKD severity increased was observed. CKD markers improved across all CKD subgroups. Relevant differences were not observed for other variables, either between non-CKD and CKD patients, or among CKD subgroups. Safety concerns were not reported.ConclusionThe safety/efficacy of OW s.c. semaglutide to improve glycemic control and weight in T2D patients with CKD is not notably lower than that in T2D patients without renal failure. CKD severity barely influences treatment response. OW s.c. semaglutide can be useful to manage T2D patients with CKD in daily clinical practice.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes with or without chronic kidney disease, semaglutide 1 mg once weekly reduced HbA1c by 0.90%-1.20%.
In plain wordsIn adults with type 2 diabetes, with or without kidney disease, weekly semaglutide lowered HbA1c by about 0.9 to 1.2 points.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction
Study
n = 486
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Measurements
HbA1c reduction
0.9 to 1.2%
all patients
Source sentences
Summary
Treatment reduced HbA1c by 0.90%-1.20%.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on semaglutide, HbA1c reduction did not differ relevantly between patients with and without CKD or among CKD subgroups.
In plain wordsIn adults with type 2 diabetes on semaglutide, kidney disease and its severity made no relevant difference to HbA1c lowering.
Peptide
Semaglutide
Outcome
No significant changeHbA1c response in CKD versus non-CKD and across CKD subgroups
Study
n = 486
Comparator
Patients without CKD
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Relevant differences were seen neither between non-CKD and CKD patients nor among CKD subgroups.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501302
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes with or without chronic kidney disease, semaglutide produced notable weight loss in both groups.
In plain wordsIn adults with type 2 diabetes, with or without kidney disease, semaglutide led to notable weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss
Study
n = 486
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Notable weight losses were achieved in both non-CKD and CKD patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501303
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on semaglutide, median weight loss at 6 months was smaller in patients with CKD (4.50 kg) than without (5.90 kg).
In plain wordsIn adults with type 2 diabetes on semaglutide, people with kidney disease lost somewhat less weight at 6 months than those without.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in non-CKD versus CKD at 6 months
Study
n = 486
Comparator
Patients without CKD
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Median weight reduction
5.9 kg
non-CKD
Median weight reduction
4.5 kg
CKD
Source sentences
Summary
The median reduction was higher in the former at 6 months (5.90 kg vs. 4.50 kg, P = 0.008) and at end of study (6.90 kg vs. 5.00 kg, P = 0.087).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501304
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on semaglutide, the difference in median weight loss at end of study between non-CKD (6.90 kg) and CKD patients (5.00 kg) was not significant.
In plain wordsIn adults with type 2 diabetes on semaglutide, at study end, weight loss did not differ significantly between people with and without kidney disease.
Peptide
Semaglutide
Outcome
No significant changeWeight loss in non-CKD versus CKD at end of study
Study
n = 486
Comparator
Patients without CKD
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Median weight reduction
6.9 kg
non-CKD
Median weight reduction
5 kg
CKD
Source sentences
Summary
and at end of study (6.90 kg vs. 5.00 kg, P = 0.087).
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501305
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on semaglutide, a trend toward slightly lower weight loss was observed as CKD severity increased.
In plain wordsIn adults with type 2 diabetes on semaglutide, weight loss tended to be slightly smaller with more severe kidney disease.
Peptide
Semaglutide
Outcome
No significant changeWeight loss trend by CKD severity
Study
n = 486
Comparator
Less severe CKD
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
A trend toward slightly lower weight losses as CKD severity increased was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501306
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and CKD on semaglutide, CKD markers improved across all CKD subgroups.
In plain wordsIn adults with type 2 diabetes and kidney disease on semaglutide, kidney disease markers improved in every severity group.
Peptide
Semaglutide
Outcome
Direction not reportedCKD markers
Study
n = 190
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
CKD markers improved across all CKD subgroups.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501307
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes on semaglutide, no relevant differences in other variables were seen between non-CKD and CKD patients or among CKD subgroups.
In plain wordsIn adults with type 2 diabetes on semaglutide, other measures did not differ relevantly between people with and without kidney disease.
Peptide
Semaglutide
Outcome
No significant changeOther variables in CKD versus non-CKD and across CKD subgroups
Study
n = 486
Comparator
Patients without CKD
Analysis
Secondary
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Relevant differences were not observed for other variables, either between non-CKD and CKD patients, or among CKD subgroups.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501308
09HumanObservational studySafety outcome
In adults with type 2 diabetes with or without chronic kidney disease, no safety concerns were reported with semaglutide.
In plain wordsIn adults with type 2 diabetes, with or without kidney disease, no safety concerns were reported with semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSafety concerns
Study
n = 486
Outcome group
Adverse events · Whole body
Studied dose
1 mg · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Safety concerns were not reported.
1 context sentence(design, population, supporting numbers)
Summary · context
This is an observational, ambispective, multicenter, nationwide, real-world study designed to compare safety/efficacy of OW s.c. 1 mg semaglutide in T2D patients with or without CKD.
Show in the study text Report a problemFND-3795501309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.